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Bacterial meningitis is an acute inflammatory disease of the central nervous system with a mortality rate of
up to 30%. Excessive stimulation of the host immune system by bacterial surface components contributes to
this devastating outcome. In vitro studies have shown that protein tyrosine kinase inhibitors are highly effective
in preventing the release of proinflammatory cytokines induced by pneumococcal cell walls in microglia. In a
well-established rat model, intracisternal injection of purified pneumococcal cell walls induced meningitis
characterized by increases in the regional cerebral blood flow and intracranial pressure, an influx of leuko-
cytes, and high concentrations of tumor necrosis factor alpha (TNF-) in the cerebrospinal fluid. Compared
with the values at the beginning of the experiment, intraperitoneal injection of tyrphostin AG 126 reduced the
increases in regional cerebral blood flow (at 6 h, 127%  14% versus 222%  51% of the baseline value; P <
0.05) and intracranial pressure (at 6 h, 0.8  2.4 versus 5.4  2.0 mm of Hg; P < 0.05), the influx of leukocytes
(at 6 h, 1,336  737 versus 4,350  2,182 leukocytes/l; P < 0.05), and the TNF- concentration (at 6 h, 261
 188 versus 873  135 pg/l; P < 0.05). These results demonstrate that inhibition of AG 126-sensitive
tyrosine kinase pathways may provide new approaches for preventing excessive inflammation and reducing the
increases in blood flow and intracranial pressure in the acute phase of bacterial meningitis.
Streptococcus pneumoniae is the major pathogen that causes
bacterial meningitis in children and adults (24). Surprisingly
devastating, even in the context of effective antibiotics, is the
poor outcome of the disease, which has a mortality rate of up
to 34% and results in permanent sequelae in up to 50% of the
survivors (9).
Two major mechanisms that cause damage in the central
nervous system have been proposed: (i) direct toxic effects of
pneumococci (5) and (ii) excessive stimulation of the host
immune system by the bacterial surface (2, 28). An important
stimulus is the multilayered network of peptidoglycan that
makes up the pneumococcal cell wall (PCW) (27). Purified
PCW induces meningeal inflammation which is comparable to
the acute inflammation caused by living bacteria, including the
clinical hallmarks of the disease, such as an influx of leukocytes
and increases in the intracranial pressure (ICP) and regional
cerebral blood flow (rCBF) (2, 28, 31). The immunostimula-
tory effect of cell wall components is clinically important (34)
because antibiotic lysis of bacteria induces the release of these
components (11). Moreover, the concentration of the cell wall
components in the cerebrospinal fluid (CSF) correlates signif-
icantly with the outcome of the disease (23).
It has been shown that heat-killed pneumococci, soluble
peptidoglycan, and PCW induce signaling through Toll-like
receptor 2 (33, 35). The downstream signaling involves activa-
tion of mitogen-activated protein kinases (MAPK) erk 1/2
(p44/42MAPK) and p38, which has been demonstrated in astro-
cytes (25), microglia (14), and primary cerebral microvascular
endothelial cells (33). Inhibition of the MAPK pathway in vitro
reduces the production of tumor necrosis factor alpha
(TNF-) and nitric oxide induced by PCW (25). Specific inhi-
bition of a protein tyrosine kinase that also controls MAPK erk
1/2 by tyrphostin AG 126 attenuates the release of proinflam-
matory cytokines in mouse microglial cells and decreases the
number of invading leukocytes in the CSF (14). AG 126 is a
selective protein tyrosine kinase inhibitor that interferes with
substrate binding rather than with ATP binding by the corre-
sponding kinase.
Tyrosine kinase inhibitors block experimental autoimmune
encephalomyelitis by reducing lymphocyte entry into the cen-
tral nervous system (7, 8). In a sepsis model AG 126 protects
mice against endotoxin toxicity, probably by blocking TNF-
and nitric oxide production (18).
In a well-established rat model of meningitis (19, 31), we
induced meningeal inflammation with PCW, a stimulus that
obviates any interference by bacterial metabolism and mimics
the inflammatory burst caused by bacterial lysis. We tested the
effect of AG 126, a protein tyrosine kinase inhibitor, on the
detrimental hallmarks of early meningitis, including leukocyte
influx, TNF- production, an increase in the blood flow, and an
increase in the ICP.
MATERIALS AND METHODS
Animal model. We used a well-characterized model of the acute phase of
bacterial meningitis (19, 31). In brief, male Wistar rats (280 to 330 g) were
anesthetized with thiopental (Trapanal; Byk Gulden, Konstanz, Germany) by
injecting 100 mg/kg intraperitoneally, followed by 15 mg/kg if required, for the
whole experiment, and they were mechanically ventilated (AP-10; K. Effer-
berger, Pfaffing, Germany). The terminal expiratory partial CO2 pressure
* Corresponding author. Mailing address: Department of Neurol-
ogy, Charite´, 10098 Berlin, Germany. Phone: 49 30 450 560104. Fax: 49
30 450 560942. E-mail: joerg.weber@charite.de.
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(pCO2), the arterial blood pressure (determined with a femoral catheter), the
ICP (determined with a catheter in the cisterna magna and Statham P10 EZ
pressure transducers [Spectramed, Oxnard, Calif.]), and the rCBF (determined
by laser-Doppler flowmetry parietally through thinned bone with a PeriFlux 4001
Master [Perimed, Ja¨rfa¨lla, Sweden]) were measured continuously. After a stable
rCBF baseline was recorded (30 min), 75 l of CSF was withdrawn and replaced
by an equal volume of sample.
The ICP data were expressed as the difference between the value obtained and
the value at the beginning of the experiment (in millimeters of Hg), and rCBF
data were expressed as a percentage of the baseline value.
At the beginning of each experiment and then at 2-h intervals, blood samples
were taken to determine arterial pO2, pCO2, and pH (COMPACT 1; AVL List,
Graz, Austria). Leukocytes in the blood and CSF were counted before and after
the experiment.
PCW preparation. PCW were purified as described previously (28, 33), with
minor modifications. Unencapsulated S. pneumoniae R6 was cultured in chem-
ically defined medium, heat killed, and mechanically disintegrated by using
0.1-mm beads. The suspension was digested with DNase (Promega, Mannheim,
Germany) and RNase (U.S. Biochemical Corp., Cleveland, Ohio), treated with
trypsin (with 10 mM CaCl2; Sigma-Aldrich Chemie Gmbh), and after centrifu-
gation (23,000  g, 20 min) resuspended in 2% sodium dodecyl sulfate (Serva,
Heidelberg, Germany); this was followed by extensive washing. The purified cell
walls were resuspended in phosphate-buffered saline at an optical density at 620
nm of 1 (equivalent to 108 CFU/ml), and stored at 20°C. The composition of
PCW has been described previously (15).
Experimental groups. Control animals were inoculated intracisternally with
pyrogen-free saline (n  7), and animals with meningitis were inoculated with
PCW (n 7). Tyrphostin AG 126 (Calbiochem-Novabiochem Corp., San Diego,
Calif.), dissolved in 200 l of dimethyl sulfoxide, was inoculated intraperitoneally
2 h before induction of meningitis (7.5 mg/kg [n  7] or 15 mg/kg [n  9]) or 1 h
after induction of meningitis (15 mg/kg [n 6] or 30 mg/kg [n 4]). In untreated
controls 200 l of dimethyl sulfoxide was injected intraperitoneally (n  7).
Statistical analysis. All data were expressed as means  standard deviations.
The means of independent groups were compared by one-way analysis of vari-
ance and the Student-Newman-Keuls multiple-comparison test and by the Stu-
dent t test for two groups. A P value of 0.05 was considered significant.
RESULTS
Tyrphostin AG 126 prevented the PCW-induced increase in
rCBF. Intracisternal injection of PCW resulted in a slow in-
crease in rCBF over 6 h (Fig. 1A), as previously described (19,
31). Pretreatment with AG 126 reduced the increase in the
rCBF in a dose-dependent manner compared to the increase in
animals with untreated meningitis at 3 h (with 7.5 mg of Ag 126
per kg, 133%  18% versus 161%  22% [P  0.05]; with 15
mg/kg, 120%  15% [P  0.05]) and at 6 h (with 7.5 mg/kg,
153%  36% versus 222%  51% [P  0.05]; with 15 mg/kg,
127%  14% [P  0.05]; linear correlation, r2  0.5260 [P 
0.001]) (Fig. 1A). Administration of AG 126 1 h after challenge
with PCW was also effective when 15 mg/kg was used (at 3 h,
130%  12% [P  0.05]; at 6 h, 150%  18% [P  0.05]) and
when 30 mg/kg was used (Fig. 1A). AG 126 treatment alone
did not alter rCBF in control animals (Fig. 1B).
Tyrphostin AG 126 prevented the PCW-induced increase in
ICP. Inflammatory hyperemia contributes to ICP. Therefore,
we asked whether a reduction in the cerebral blood flow re-
sulted in attenuation of ICP in AG 126-treated animals. Pre-
treatment with 7.5 mg of AG 126 per kg, as well as with 15 mg
of AG 126 per kg, reduced the ICP significantly compared to
the ICP in untreated rats with meningitis at 3 h (with 7.5 mg of
AG 126 per kg, 0.7 1.6 versus 2.0 1.0 mm of Hg [difference
not significant]; with 15 mg of AG 126 per kg, 0.6  1.0 mm of
Hg [P 0.05]) (Fig. 2A) and at 6 h (with 7.5 mg of AG 126 per
kg, 1.9  2.1 versus 5.4  2.0 mm of Hg [P  0.05]; with 15
mg/kg, 0.8  2.4 mm of Hg [P  0.05]; r2  0.4394 [P  0.01])
(Fig. 2B). Posttreatment with 30 mg/kg prevented the increase
in ICP (at 3 h, 0.6  1.0 mm of Hg [P  0.05]; at 6 h, 1.1  1.9
mm of Hg [P  0.05]), whereas posttreatment with 15 mg/kg
did not prevent the increase (at 6 h, 6.9  4.6 mm of Hg
[difference not significant]). In control animals and AG 126-
treated controls there was no change in ICP over time (data
not shown).
Tyrphostin AG 126 reduced the PCW-induced invasion of
the CSF by leukocytes. Invasion by leukocytes is a hallmark of
bacterial meningitis. AG 126 reduced the invasion of the sub-
arachnoidal space by leukocytes in a dose-dependent manner
(with 7.5 mg of AG 126 per kg, 1,984  1,066 versus 4,350 
2,182 leukocytes/l [P  0.05]; with 15 mg of AG 126 per kg,
1,336  737 leukocytes/l [P  0.05]; linear correlation, r2 
0.4182 [P  0.05]) (Fig. 2C). The 30-mg/kg AG 126 treatment
inhibited leukocyte invasion of the CSF even 1 h after induc-
tion of meningitis (1,011  936 leukocytes/l [P  0.05]),
whereas the 15-mg/kg posttreatment was not effective (4,439
1,024 leukocytes/l [difference not significant]).
Tyrphostin AG 126 reduced the TNF- concentrations in
the CSF. TNF- is thought to be one of the key proinflamma-
tory cytokines in meningitis (1, 17). Pretreatment of animals
with meningitis with AG 126 reduced the concentration of
TNF- in the CSF significantly compared to the concentration
in untreated animals with meningitis (with 15 mg of AG 126
per kg, 261 188 versus 873 135 pg/ml [P 0.05]) (Fig. 2D).
Posttreatment with 15 mg/kg was not effective, but posttreat-
ment with 30 mg/kg decreased the concentration of TNF-
significantly (188  97 pg/ml [P  0.05]). The TNF- levels
were not different in controls and AG 126-treated controls (18
 3 and 28  10 pg/ml).
AG 126 treatment had no effect on physiological parame-
ters. Body temperature, mean arterial blood pressure, and
arterial pH, pO2, and pCO2 were measured every hour, and
FIG. 1. Effect of tyrphostin AG 126 on rCBF in experimental men-
ingitis. (A) Meningitis induced a slow increase in rCBF, which was
significantly reduced by treatment with 15 mg of AG 126 per kg 2 h
before induction of meningitis (F) or by treatment with 30 mg of AG
126 per kg 1 h after induction of meningitis (J). An asterisk indicates
that the P value is0.05 (as determined by analysis of variance and the
Student-Newman-Keuls post hoc test). (B) rCBF was stable over time
and did not change in control animals. The values are means  stan-
dard deviations.
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the values were comparable for all experimental groups (Table
1). Blood leukocytes were counted at the beginning and the
end of the experiment, and there were no differences among
the groups.
DISCUSSION
Adjunctive therapy in pneumococcal meningitis targets the
overwhelming immune response due to the release of highly
inflammatory components of lysed bacteria. Recently, pre-
treatment with dexamethasone has been proven to decrease
the mortality and morbidity from pneumococcal meningitis
(9). Further improvement must be based on a detailed under-
standing of the triggers of this immune response, as well as
specifically targeted intervention in the inflammatory cascade.
Most potential pharmacologic agents that have been identified
recently do not cross the blood-brain barrier and therefore
require intracisternal administration. The ability of AG 126 to
cross this barrier makes it an attractive potential therapeutic
agent.
Here we show that specific inhibition of a protein tyrosine
kinase, most likely upstream of p42/44MAPK, reduced the in-
creases in the rCBF and ICP, as well as the influx of leukocytes
FIG. 2. Tyrphostin AG 126 reduced ICP in a dose-dependent man-
ner 3 h (A) and 6 h (B) after induction of meningitis. The CSF white
cell count (C) and the TNF- concentration (D) were also significantly
reduced at 6 h compared to the values obtained for untreated animals
with meningitis. The values are means  standard deviations. An
asterisk indicates that the P value is 0.05 (as determined by analysis
of variance).
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and the TNF- concentration in the CSF in the acute phase of
experimental meningitis.
AG 126 prevented an increase in rCBF, a measure of local
vasodilatation, in a dose-dependent manner. Furthermore,
treatment of the animals 1 h after induction of meningitis still
inhibited the increase in rCBF. This is consistent with signifi-
cantly improved hemodynamic parameters seen in tyrphostin-
treated animals with multiorgan failure caused by Escherichia
coli (26).
Clinically, increased ICP in the acute phase of bacterial
meningitis is enormously important and may be attributed to at
least three mechanisms (21): (i) vasogenic edema due to ex-
travasation of plasma compounds and hyperemia; (ii) cytotoxic
edema caused by toxins released from activated leukocytes
(13), glia (20), endothelial cells (12), and bacteria; and (iii) an
increase in CSF outflow resistance (22). Decreased ICP in
tyrphostin-treated animals may result from attenuated hyper-
emia, as well as reduced leukocyte recruitment and TNF-
concentrations in the CSF.
Leukocyte influx into the CSF, the hallmark of bacterial
meningitis, was significantly reduced in AG 126-treated ani-
mals compared to that in untreated animals. Reducing the
leukocyte influx is believed to have potential therapeutic ben-
efits because high numbers of leukocytes correlate with an
unfavorable outcome (3), and blocking leukocyte invasion at-
tenuates brain edema, an increase in the ICP, hyperemia, and
neuronal damage and improves survival in experimental men-
ingitis (4, 29, 32). In a model of zymosan-induced peritonitis
AG 126 also inhibited the influx of polymorphonuclear leuko-
cytes in a dose-dependent manner (10). Additionally, protein
tyrosine phosphorylation mediates TNF--induced endothelial
neutrophil adhesion in vitro (16). Autoimmune encephalomy-
elitis is suppressed by tyrosine kinase inhibitors (6, 7), most
likely by inhibition of invasion of the brain parenchyma by
leukocytes (8).
TNF- is thought to be one of the key cytokines in bacterial
meningitis, as the level of TNF- is elevated in the CSF of
meningitis patients (30) and in experimental models (17), and
it dramatically accelerates experimental pneumococcal menin-
gitis (1). Production of TNF- requires p42/44MAPK activation,
as shown in macrophages (18), astrocytes (25), and microglia
(14). AG 126-treated mice survive a lipopolysaccharide-in-
duced lethal shock, and the protection is correlated with de-
creased TNF- production (18). Accordingly, AG 126 treat-
ment reduced TNF- levels in the CSF of animals with
meningitis in the present study.
In conclusion, our study showed that an AG 126-sensitive
protein tyrosine kinase is important in the early phase of pneu-
mococcal meningitis. AG 126 effectively inhibited blood flow
and an increase in the ICP and reduced the leukocyte influx
and TNF- concentration in the CSF. These results suggest
that inhibition of selective tyrosine kinase phosphorylation
may provide new approaches for decreasing the excessive in-
flammatory response caused by antibiotic lysis of bacteria and
the release of highly inflammatory PCW.
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